ReviewSensors (Basel, Switzerland)2025
Nanomaterial-Based Sensing Systems to Detect Neuropharmaceutical Compounds and Neurotransmitters.
Review in Sensors (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ethical Precision in Nanoscale Brain Interfacing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Recent Advances in Electrochemical Biosensors for the Detection of Milk Adulterants.Biosensors · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review explores the application of nanomaterial-based sensing systems for precisely detecting neuropharmaceutical compounds and neurotransmitters, delving into the connections between nanotechnology and neuropharmacology. Nanotechnology appears as a promising solution for many significant challenges posed by the complexities of the brain's biochemical nature. Using nanoscale materials, scientists have created novel sensors with high selectivity, sensitivity, and adaptability. Developing neuropharmaceutical compounds and monitoring their side effects on our neurological system raised the need for these nanomaterial-based sensors. In this review, we demonstrate the effectiveness of these technologies in real-time neuroactive compound detection and monitoring by illuminating the underlying principles through an examination of significant studies and recent developments. This review also highlights collaborative efforts at the intersection of nanotechnology and neuropharmacology and their direct and indirect effects on the understanding and controlling several neurological disorders. This review covers both sensors under research and those already applied in vivo or clinical monitoring of drug side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.